Journal of Molecular Neuroscience

, Volume 59, Issue 2, pp 177–183 | Cite as

Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples

  • Andrea TamasEmail author
  • Andras Javorhazy
  • Dora Reglodi
  • Donat Peter Sarlos
  • Daniel Banyai
  • David Semjen
  • Jozsef Nemeth
  • Beata Lelesz
  • Daniel Balazs Fulop
  • Zalan Szanto


Numerous studies investigated the localization of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors in different tumors and described the effects of analogs on tumor growth to show its potential role in oncogenesis. Recently, our research group has found significantly lower levels of PACAP27-like immunorreactivity (LI) and PACAP38-LI in different human samples of primary small cell lung cancer and colon cancer compared to normal healthy tissues. There are only few human studies showing the presence of PACAP and its receptors in urogenital tumors; therefore, the aim of the present study was to compare PACAP-LI in different healthy and pathological human samples from urogenital organs (kidney, urinary bladder, prostate, testis) with radioimmunoassay (RIA) method. Similar to our earlier observations, the PACAP27-LI was significantly lower compared to PACAP38-LI in all samples. We did not find significant alterations in PACAP-LI between healthy and tumoral samples from the urinary bladder and testis. On the other hand, we found significantly lower PACAP38-LI level in kidney tumors compared with healthy tissue samples, and we showed higher PACAP27-LI in prostatic cancer compared to samples from benign prostatic hyperplasia. These data indicate that PACAP levels of different tissue samples are altered under pathological conditions suggesting a potential role of PACAP in the development of different urogenital tumors.


PACAP38 PACAP27 Kidney Prostate Benign prostatic hyperplasia Urinary bladder radioimmunoassay 



This study was supported by the following grants: OTKA K104984, Arimura Foundation, TÁMOP-4.1.1.C-13/1/KONV-2014-0001, TÁMOP-4.2.2.B-15/KONV-2015-0011, TÁMOP 4.2.4.A/2-11-1-2012-0001 “National Excellence Program,” Janos Bolyai Research Scholarship of Hungarian Academy of Sciences, MTA-PTE “Lendulet” Program. The authors also thank all the volunteers.


  1. Arimura A, Somogyvari-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C (1991) Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129:2787–2789CrossRefPubMedGoogle Scholar
  2. Arimura A, Li M, Batuman V (2006a) Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107:661–668CrossRefPubMedGoogle Scholar
  3. Arimura A, Li M, Batuman V (2006b) Treatment of renal failure associated with multiple myeloma and other diseases by PACAP-38. Ann N Y Acad Sci 1070:1–4CrossRefPubMedGoogle Scholar
  4. Arms L, Vizzard MA (2011) Neuropeptides in lower urinary tract function. Handb Exp Pharmacol 202:395–423CrossRefPubMedGoogle Scholar
  5. Banki E, Degrell P, Kiss P, Kovacs K, Kemeny A, Csanaky K, Duh A, Nagy D, Toth G, Tamas A, Reglodi D (2013) Effect of PACAP treatment on kidney morphology and cytokine expression in rat diabetic nephropathy. Peptides 42:125–130CrossRefPubMedGoogle Scholar
  6. Banki E, Kovacs K, Nagy D, Juhasz T, Degrell P, Csanaky K, Kiss P, Jancso G, Toth G, Tamas A, Reglodi D (2014) Molecular mechanisms underlying the nephroprotective effects of PACAP in diabetes. J Mol Neurosci 54:300–309CrossRefPubMedGoogle Scholar
  7. Borzsei R, Mark L, Tamas A, Bagoly T, Bay C, Csanaky K, Banki E, Kiss P, Vaczy A, Horvath G, Nemeth J, Szauer E, Helyes Z, Reglodi D (2009) Presence of pituitary adenylate cyclase activating polypeptide-38 in human plasma and milk. Eur J Endocrinol 160:561–565CrossRefPubMedGoogle Scholar
  8. Bossowska A, Crayton R, Radziszewski P, Kmiec Z, Majewski M (2009) Distribution and neurochemical characterization of sensory dorsal root ganglia neurons supplying porcine urinary bladder. J Physiol Pharmacol 60(Suppl 4):77–81PubMedGoogle Scholar
  9. Brubel R, Boronkai A, Reglodi D, Racz B, Nemeth J, Kiss P, Lubics A, Toth G, Horvath G, Varga T, Szogyi D, Fonagy E, Farkas J, Barakonyi A, Bellyei S, Szereday L, Koppan M, Tamas A (2010) Changes in the expression of pituitary adenylate cyclase-activating polypeptide in the human placenta during pregnancy and its effects on the survival of JAR choriocarcinoma cells. J Mol Neurosci 42:450–458CrossRefPubMedGoogle Scholar
  10. Brubel R, Horvath G, Reglodi D, Lubics A, Tamas A, Kiss P, Laszlo E, Nemeth J, Mark L, Szakaly P (2011) Presence of pituitary adenylate cyclase activating polypeptide and its type I receptor in the rat kidney. Transplant Proc 43:1297–1299CrossRefPubMedGoogle Scholar
  11. Brubel R, Kiss P, Vincze A, Varga A, Varnagy A, Bodis J, Mark L, Jambor E, Maasz G, Hashimoto H, Helyes Z, Toth G, Tamas A, Koppan M, Reglodi D (2012) Effects of pituitary adenylate cyclase activating polypeptide on human sperm motility. J Mol Neurosci 48:623–630CrossRefPubMedGoogle Scholar
  12. Busto R, Carrero I, Guijarro LG, Solano RM, Zapatero J, Noguerales F, Prieto JC (1999) Expression, pharmacological, and functional evidence for PACAP/VIP receptors in human lung. Am J Physiol 277(1 Pt 1):L42–L48PubMedGoogle Scholar
  13. Busto R, Prieto JC, Bodega G, Zapatero J, Carrero I (2000) Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides 21:265–269CrossRefPubMedGoogle Scholar
  14. Busto R, Prieto JC, Bodega G, Zapatero J, Fogue L, Carrero I (2003) VIP and PACAP receptors coupled to adenylyl cyclase in human lung cancer: a study in biopsy specimens. Peptides 24:429–436CrossRefPubMedGoogle Scholar
  15. Cohen JR, Resnick DZ, Niewiadomski P, Dong H, Liau LM, Waschek JA (2010) Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures. BMC Cancer 10:676CrossRefPubMedPubMedCentralGoogle Scholar
  16. D’Amico AG, Scuderi S, Saccone S, Castorina A, Drago F, D’Agata V (2013) Antiproliferative effects of PACAP and VIP in serum-starved glioma cells. J Mol Neurosci 51:503–513CrossRefPubMedGoogle Scholar
  17. Dufes C, Alleaume C, Montoni A, Olivier JC, Muller JM (2003) Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro. J Mol Neurosci 21:91–102CrossRefPubMedGoogle Scholar
  18. Fahrenkrug J, Hannibal J (1998) PACAP in visceral afferent nerves supplying the rat digestive and urinary tracts. Ann N Y Acad Sci 865:542–546CrossRefPubMedGoogle Scholar
  19. Garcia-Fernandez MO, Bodega G, Solano RM, Ruiz-Villaespesa A, Sanchez-Chapado M, Carmena MJ, Prieto JC (2002) Expression and distribution of pituitary adenylate cyclase-activating peptide in human prostate and prostate cancer tissues. Regul Pept 110:9–15CrossRefPubMedGoogle Scholar
  20. Garcia-Fernandez MO, Solano RM, Carmena MJ, Busto R, Bodega G, Ruiz-Villaespesa A, Prieto JC, Sanchez-Chapado M (2003) Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue. Peptides 24:893–902CrossRefPubMedGoogle Scholar
  21. Gardiner SM, Rakhit T, Kemp PA, March JE, Bennett T (1994) Regional haemodynamic responses to pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in conscious rats. Br J Pharmacol 111:589–597CrossRefPubMedPubMedCentralGoogle Scholar
  22. Germano PM, Lieu SN, Xue J, Cooke HJ, Christofi FL, Lu Y, Pisegna JR (2009) PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells. J Mol Neurosci 39:391–401CrossRefPubMedGoogle Scholar
  23. Hannibal J, Fahrenkrug J (1995) Expression of pituitary adenylate cyclase activating polypeptide (PACAP) gene by rat spermatogenic cells. Regul Pept 55:111–115CrossRefPubMedGoogle Scholar
  24. Harmar AJ, Sheward WJ, Morrison CF, Waser B, Gugger M, Reubi JC (2004) Distribution of the VPAC2 receptor in peripheral tissues of the mouse. Endocrinology 145:1203–1210CrossRefPubMedGoogle Scholar
  25. Hatanaka M, Tanida M, Shintani N, Isojima Y, Kawaguchi C, Hashimoto H, Kakuda M, Haba R, Nagai K, Baba A (2008) Lack of light-induced elevation of renal sympathetic nerve activity and plasma corticosterone levels in PACAP-deficient mice. Neurosci Lett 444:153–156CrossRefPubMedGoogle Scholar
  26. Hautmann M, Friis UG, Desch M, Todorov V, Castrop H, Segerer F, Otto C, Schutz G, Schweda F (2007) Pituitary adenylate cyclase activating polypeptide stimulates renin secretion via activation of PAC1 receptors. J Am Soc Nephrol 18:1150–1156CrossRefPubMedGoogle Scholar
  27. Hong X, Huang L, Song Y (2008) Role of vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide in the vaginal wall of women with stress urinary incontinence and pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 19:1151–1157CrossRefPubMedGoogle Scholar
  28. Horvath G, Mark L, Brubel R, Szakaly P, Racz B, Kiss P, Tamas A, Helyes Z, Lubics A, Hashimoto H, Baba A, Shintani S, Furjes G, Nemeth J, Reglodi D (2010a) Mice deficient in pituitary adenylate cyclase activating polypeptide display increased sensitivity to renal oxidative stress in vitro. Neurosci Lett 469:70–74CrossRefPubMedGoogle Scholar
  29. Horvath G, Racz B, Reglodi D, Kovacs K, Kiss P, Gallyas F Jr, Bognar Z, Szabo A, Magyarlaki T, Laszlo E, Lubics A, Tamas A, Toth G, Szakaly P (2010b) Effects of PACAP on mitochondrial apoptotic pathways and cytokine expression in rats subjected to renal ischemia–reperfusion. J Mol Neurosci 42:411–418CrossRefPubMedGoogle Scholar
  30. Horvath G, Brubel R, Kovacs K, Reglodi D, Opper B, Ferencz A, Szakaly P, Laszlo E, Hau L, Kiss P, Tamas A, Racz B (2011) Effects of PACAP on oxidative stress-induced cell death in primary rat kidney and human hepatocyte cell cultures. J Mol Neurosci 43:67–75CrossRefPubMedGoogle Scholar
  31. Ishizuka O, Alm P, Larsson B, Matthiason A, Andersson KE (1995) Facilitatory effect of pituitary adenylate cyclase activating polypeptide on micturition in normal, conscious rat. Neuroscience 66:1009–1014CrossRefPubMedGoogle Scholar
  32. Jakab B, Reglodi D, Jozsa R, Hollosy T, Tamas A, Lubics A, Lengvari I, Oroszi G, Szilvassy Z, Szolcsanyi J, Nemeth J (2004) Distribution of PACAP-38 in the central nervous system of various species determined by a novel radioimmunoassay. J Biochem Biophys Methods 61:189–198CrossRefPubMedGoogle Scholar
  33. Khan AM, Li M, Brant E, Maderdrut JL, Majid DS, Simon EE, Batuman V (2011) Renoprotection with pituitary adenylate cyclase-activating polypeptide in cyclosporine A-induced nephrotoxicity. J Investig Med 59:793–802CrossRefPubMedGoogle Scholar
  34. Lacombe A, Lelievre V, Roselli CE, Salameh W, Lue YH, Lawson G, Muller JM, Waschek JA, Vilain E (2006) Delayed testicular aging in pituitary adenylate cyclase-activating peptide (PACAP) null mice. Proc Natl Acad Sci U S A 103:3793–3798CrossRefPubMedPubMedCentralGoogle Scholar
  35. Lam HC, Takahashi K, Ghatei MA, Kanse SM, Polak JM, Bloom SR (1990) Binding sites of a novel neuropeptide pituitary adenylate cyclase activating polypeptide in the rat brain and lung. Eur J Biochem 193:725–729CrossRefPubMedGoogle Scholar
  36. Le SV, Yamaguchi DJ, McArdle CA, Tachiki K, Pisegna JR, Germano P (2002) PAC1 and PACAP expression, signaling, and effect on the growth of HCT8, human colonic tumor cells. Regul Pept 109:115–125CrossRefPubMedGoogle Scholar
  37. Lee JH, Lee JY, Rho SB, Choi JS, Lee DG, An S, Oh T, Choi DC, Lee SH (2014) PACAP inhibits tumor growth and interferes with clusterin in cervical carcinomas. FEBS Lett 588:4730–4739CrossRefPubMedGoogle Scholar
  38. Leyton J, Coelho T, Coy DH, Jakowlew S, Birrer MJ, Moody TW (1998) PACAP(6–38) inhibits the growth of prostate cancer cells. Cancer Lett 125:131–139CrossRefPubMedGoogle Scholar
  39. Leyton J, Gozes Y, Pisegna J, Coy D, Purdom S, Casibang M, Zia F, Moody TW (1999) PACAP(6–38) is a PACAP receptor antagonist for breast cancer cells. Breast Cancer Res Treat 56:177–186CrossRefPubMedGoogle Scholar
  40. Li M, Arimura A (2003) Neuropeptides of the pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide/growth hormone-releasing hormone/secretin family in testis. Endocrine 20:201–214CrossRefPubMedGoogle Scholar
  41. Li M, Maderdrut JL, Lertora JJL, Batuman V (2007) Intravenous infusion of pituitary adenylate cyclase activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study. Peptides 28:1891–1895CrossRefPubMedGoogle Scholar
  42. Li M, Maderdrut JL, Lertora JJL, Arimura A, Batuman V (2008) Renoprotection by pituitary adenylate cyclase activating polypeptide in multiple myeloma and other kidney diseases. Regul Pept 145:24–32CrossRefPubMedGoogle Scholar
  43. Li M, Balamuthusamy S, Khan AM, Maderdrut JL, Simon EE, Batuman V (2011) Pituitary adenylate cyclase activating polypeptide prevents cisplatin-induced renal failure. J Mol Neurosci 43:58–66CrossRefPubMedGoogle Scholar
  44. Mirabella N, Squillacioti C, Germano G, Varricchio E, Paino G (2001) Pituitary adenylate cyclase activating polypeptide (PACAP) immunoreactivity in the ureter of the duck. Cell Tissue Res 305:341–349CrossRefPubMedGoogle Scholar
  45. Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, Minamino N, Arimura A (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170:643–648CrossRefPubMedGoogle Scholar
  46. Moller K, Zhang YZ, Hakanson R, Luts A, Sjolund B, Uddman R, Sundler F (1993) Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience 57:725–732CrossRefPubMedGoogle Scholar
  47. Moody TW, Zia F, Makheja A (1993) Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells. Peptides 14:241–246CrossRefPubMedGoogle Scholar
  48. Moody TW, Leyton J, Casibang M, Pisegna J, Jensen RT (2002) PACAP-27 tyrosine phosphorylates mitogen activated protein kinase and increases VEGF mRNAs in human lung cancer cells. Regul Pept 109:135–140CrossRefPubMedGoogle Scholar
  49. Moody TW, Chan D, Fahrenkrug J, Jensen RT (2003) Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des 9:495–509CrossRefPubMedGoogle Scholar
  50. Moody TW, Osefo N, Nuche-Berenguer B, Ridnour L, Wink D, Jensen RT (2012) Pituitary adenylate cyclase activating polypeptide causes tyrosine phosphorylation on the EGF receptor in lung cancer cells. J Pharmacol Exp Ther 341:873–881CrossRefPubMedPubMedCentralGoogle Scholar
  51. Nakamachi T, Sugiyama K, Watanabe J, Imai N, Kagami N, Hori M, Arat S, Shioda S (2014) Comparison of expression and proliferative effect of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors on human astrocytoma cell lines. J Mol Neurosci 54:388–394CrossRefPubMedGoogle Scholar
  52. Nakamura K, Nakamachi T, Endo K, Ito K, Machida T, Oka T, Hori M, Ishizaka K, Shioda S (2014) Distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) in the human testis and in testicular germ cell tumors. Andrologia 46:465–471CrossRefPubMedGoogle Scholar
  53. Nemeth J, Jakab B, Jozsa R, Hollosy T, Tamas A, Lubics A, Lengvari I, Kiss P, Oberritter Z, Horvath B, Szilvassy Z, Reglodi D (2007) PACAP-27 radioimmunoassay: description and application of a novel method. J Radioanal Nucl Chem 273:327–332CrossRefGoogle Scholar
  54. Olsson C, Holmgren S (1994) Distribution of PACAP (pituitary adenylate cyclase-activating polypeptide)-like and helospectin-like peptides in the teleost gut. Cell Tissue Res 277:539–547CrossRefPubMedGoogle Scholar
  55. Peeters K, Gerets HH, Princen K, Vandesande F (1999) Molecular cloning and expression of a chicken pituitary adenylate cyclase activating polypeptide receptor. Mol Brain Res 71:244–255CrossRefPubMedGoogle Scholar
  56. Reglodi D, Kiss P, Horvath G, Lubics A, Laszlo E, Tamas A, Racz B, Szakaly P (2012) Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney. Neuropeptides 46:61–70CrossRefPubMedGoogle Scholar
  57. Reubi JC (2000) In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann N Y Acad Sci 921:1–25CrossRefPubMedGoogle Scholar
  58. Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA (2000) Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 60:3105–3112PubMedGoogle Scholar
  59. Schafer H, Zheng J, Gundlach F, Günther R, Schmidt WE (1996) PACAP stimulates transcription of c-Fos and c-Jun and activates the AP-1 transcription factor in rat pancreatic carcinoma cells. Biochem Biophys Res Commun 221:111–116CrossRefPubMedGoogle Scholar
  60. Sherwood NM, Krueckl SL, McRory JE (2000) The origin and function of the pituitary adenylate cyclase activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21:619–670PubMedGoogle Scholar
  61. Shioda S, Nakajo S, Nakai Y, Arimura A (1998) Pituitary adenylate cyclase-activating polypeptide: a key player in male reproduction? Ann N Y Acad Sci 839:524–525CrossRefPubMedGoogle Scholar
  62. Sokolowska P, Nowak JZ (2008) Effects of PACAP and VIP on cAMP-generating system and proliferation of C6 glioma cells. J Mol Neurosci 36:286–291CrossRefPubMedGoogle Scholar
  63. Solano RM, Carmena MJ, Carrero I, Cavallaro S, Roman F, Hueso C, Travali S, Lopez-Fraile N, Guijarro LG, Prieto JC (1996) Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate. Endocrinology 137:2815–2822PubMedGoogle Scholar
  64. Solano RM, Carmena MJ, Busto R, Sánchez-Chapado M, Guijarro LG, Prieto JC (1999) Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate. Cell Signal 11:813–819CrossRefPubMedGoogle Scholar
  65. Szakaly P, Kiss P, Lubics A, Magyarlaki T, Tamas A, Racz B, Lengvari I, Toth G, Reglodi D (2008) Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia-reperfusion. J Mol Neurosci 36:89–96CrossRefPubMedGoogle Scholar
  66. Szakaly P, Horvath G, Kiss P, Laszlo E, Farkas J, Furjes G, Nemeth J, Reglodi D (2010) Changes in pituitary adenylate cyclase-activating polypeptide following renal ischemia-reperfusion in rats. Transplant Proc 42:2283–2286CrossRefPubMedGoogle Scholar
  67. Szanto Z, Sarszegi Z, Reglodi D, Nemeth J, Szabadfi K, Kiss P, Varga A, Banki E, Csanaky K, Gaszner B, Pinter O, Szalai Z, Tamas A (2012) PACAP immunoreactivity in human malignant tumor samples and cardiac diseases. J Mol Neurosci 48:667–673CrossRefPubMedGoogle Scholar
  68. Vacas E, Fernandez-Martinez AB, Bajo AM, Sanchez-Chapado M, Schally AV, Prieto JC, Carmena MJ (2012) Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation. Biochim Biophys Acta 1823:1676–1685CrossRefPubMedGoogle Scholar
  69. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61:283–357CrossRefPubMedGoogle Scholar
  70. Yoshiyama M, de Groat WC (2008) The role of vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide in the neural pathways controlling the lower urinary tract. J Mol Neurosci 36:227–240CrossRefPubMedPubMedCentralGoogle Scholar
  71. Zia F, Fagarasan M, Bitar K, Coy DH, Pisegna JR, Wank SA, Moody TW (1995) Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells. Cancer Res 55:4886–4891PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Andrea Tamas
    • 1
    Email author
  • Andras Javorhazy
    • 2
  • Dora Reglodi
    • 1
  • Donat Peter Sarlos
    • 2
  • Daniel Banyai
    • 2
  • David Semjen
    • 3
  • Jozsef Nemeth
    • 5
  • Beata Lelesz
    • 5
  • Daniel Balazs Fulop
    • 1
  • Zalan Szanto
    • 4
  1. 1.Department of Anatomy, MTA-PTE “Lendulet” PACAP Research TeamUniversity of PecsPecsHungary
  2. 2.Department of UrologyUniversity of PecsPecsHungary
  3. 3.Department of PathologyUniversity of PecsPecsHungary
  4. 4.Department of SurgeryUniversity of PecsPecsHungary
  5. 5.Department of Pharmacology and PharmacotherapeuticsUniversity of DebrecenDebrecenHungary

Personalised recommendations